

WRITER'S DIRECT DIAL:  
(713) 439-0108

October 2, 2009

Temp. File: 4001.003000

CERTIFICATE OF ELECTRONIC FILING

I hereby certify that this correspondence is being transmitted to the Commissioner for Patents, Alexandria, VA, via the Office electronic filing system in accordance with 37 C.F.R. § 1.6(a)(4), on the date below:

October 2, 2009

Date

Dean C. Brehm

Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

RE: *U.S. Patent No. 7,572,442; based on Application Serial No. 10/621,269; Entitled "Selected Antibody Compositions for Binding to Aminophospholipids" (As Amended); by Thorpe and Ran; UT Ref. UTSD:0893 US; Peregrine Family UTS11; Our Temp. Ref. 4001.003000*

Sir:

Attached is form PTO-1050. Errors of a minor nature are thereon corrected. The errors are due to Patent Office oversights.


There is an error in the specification at column 122, line 36, which reads "The antibodies" instead of "Certain of the antibodies". There is an error in the specification at column 187, lines 44-45, which reads "the 3G4 antibody CDR1-3 are" instead of "the 3G4 antibody, encompassing CDR1-3, are".

Correction of these errors in the specification is supported by the Supplemental Amendment submitted on October 19, 2006. Although these paragraphs were twice amended (in an amendment submitted on July 12, 2007), the original changes have been overlooked.

A Certificate of Correction is requested under 35 U.S.C. § 254. Although no fees should be required, should any fee under 37 C.F.R. § 1.20(a) be required for any reason, the Commissioner is authorized to deduct said fee from Peregrine Pharmaceuticals, Inc. Deposit Account No. 50-3493/4001.003000.

Respectfully submitted,

PEREGRINE PHARMACEUTICALS, INC.  
Customer No. 000052101

  
Shelley P.M. Fussey, Ph.D.  
Reg. No. 39,458  
Agent for Applicants

Commissioner of Patents

October 2, 2009

Page 2

bcc: BethLynn Maxwell, Ph.D., J.D.  
Ray Wheatley, M.S. (w/encl.)  
Steven W. King, Ph.D.  
Ramon M. Valencia, M.S. (w/encl.)  
Philip E. Thorpe, Ph.D. (w/encl.)  
Sophia Ran, Ph.D. (w/encl.)

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 1 of 1

PATENT NO.: 7,572,442  
APPLICATION NO.: 10/621,269  
ISSUE DATE: Aug., 11, 2009  
INVENTOR(S): PHILIP E. THORPE and SOPHIA RAN

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

At column 122, line 36, delete "The antibodies" and insert --Certain of the antibodies-- therefor.

At column 187, lines 44-45, delete "the 3G4 antibody CDR1-3 are" and insert --the 3G4 antibody, encompassing CDR1-3, are-- therefor.

In claim 8, at column 218, line 39, delete "monoclonal" and insert --monoclonal-- therefor.

In claim 9, at column 218, line 53, delete "cater" and insert --carrier-- therefor.

In claim 9, at column 218, line 61, delete "VII" and insert --VH-- therefor.

In claim 9, at column 219, line 4, delete "CDR2" and insert --CDR1-- therefor.

In claim 13, at column 219, line 20, delete "Therapeutic" and insert --therapeutic-- therefor.

In claim 13, at column 219, line 22, delete "tree" and insert --three-- therefor.

In claim 25, at column 220, line 21, delete "monoclonall" and insert --monoclonal-- therefor.

In claim 27, at column 220, line 29, delete "phannaceutical" and insert --pharmaceutical-- therefor.

In claim 27, at column 220, line 29, delete "phannaceutical" and insert --pharmaceutical-- therefor.

In claim 29, at column 220, line 38, delete "CORs" and insert --CDRs-- therefor.

In claim 29, at column 220, line 43, delete "COR1" and insert --CDR1-- therefor.

In claim 30, at column 220, line 63, delete "monoclonal" and insert --monoclonal-- therefor.

**MAILING ADDRESS OF SENDER (Please do not use customer number below):**

5353 W. Alabama, Suite 306  
Houston, TX 77056

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.